Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06360900

Synergistic Gut-brain Axis Modulation Via Vagal Stimulation and Support Therapy in Functional Dyspepsia

The study aims at evaluating physiological and patient-reported outcomes for a dual intervention approach including a stimulation device and support therapy in patients with functional dyspepsia.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02129, United States

Location status: Recruiting

Location contact

Luca McKerley Coronado

CONTACT

[email protected]

857-238-0962

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age 18-65 years old (inclusive)

  • Ability to give written consent and participate in behavioral intervention in English
  • Willingness to attend weekly treatment sessions over live video, daily self-administered transcutaneous auricular vagus nerve stimulation (taVNS) sessions, and engage in homework during treatment
  • Avoidance of alcohol, nicotine, and caffeine for 24 hours prior to study session
  • Diagnosis according to the Rome IV criteria for both epigastric pain syndrome and postprandial distress syndrome subtypes
  • Stable medical treatment for functional dyspepsia (FD) during 1 month before the study and during the study period

Exclusion criteria

  • Previous receipt of cognitive behavioral therapy (CBT) for gastrointestinal symptoms
  • Enteral or parenteral feeding
  • Previous gastrointestinal surgery, electrolyte disturbances, kidney dysfunction, renal insufficiency, or iron overload disorders
  • Estimated Glomerular Filtration Rate (eGFR) < 60
  • Medications that affect gastrointestinal motility in addition to medications or products containing tetrahydrocannabinol (THC) will be stopped at least 7 days prior to the start of the study and for the duration of the study. However, anti-depressants (SSRI's, TCA's) may be allowed in order to reduce the risk of worsening neuropsychiatric disease, though it will be up to the study team and the Principal Investigator whether subjects on anti-depressants will be able to participate in the study
  • Intellectual disability by history
  • Diabetes, mitochondrial disease, severe autonomic dysfunction, and small fiber polyneuropathy
  • No active clinical acupuncture therapy
  • Illicit drugs or opioid usage
  • History of arrhythmias
  • Current pregnancy/breastfeeding
  • Contraindications for magnetic resonance imaging (MRI) (implanted ferromagnetic objects, claustrophobia)
  • Weight > 450 lbs. (limit of the MRI table)
  • Allergy to pineapple (used in the test meal during MRI)
  • Any other condition interfering with study requirements, according to the Investigator

Treatment and study plan

Sensory device

Device

Sensory vagal nerve stimulation

Skills Building

Behavioral

Skills Building behavioral therapy

Health Education

Behavioral

Education of FD condition

Subsensory device

Device

Subsensory vagal nerve stimulation

Primary outcomes

  1. Visceral Sensitivity Index (VSI)

    Time frame: 8 weeks (post-treatment)

    GI-related anxiety; score ranging from score ranging from 0 to 75, with higher scores indicating worse outcomes

Secondary outcomes

  1. Gastric peristaltic velocity

    Time frame: 8 weeks (post-treatment)

    MRI-derived gastric motility outcome

  2. Nepean Dyspepsia Index (NDI)

    Time frame: 8 weeks (post-treatment)

    FD symptoms severity; score ranging from 0 to 100, with higher scores indicating worse outcomes

Study contacts

Contact information is provided by the study sponsor or research team.

Luca McKerley Coronado

CONTACT

[email protected]

857-238-0962

Sponsors and collaborators

Lead sponsor

Spaulding Rehabilitation Hospital

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Registry information

Acronym: CONVERGE

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
Apr 11, 2024
Registry last updated
Jul 15, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.